Fabio Grassi, is a leading expert in mucosal immunology. He earned his degree in Medicine at the University of Pavia and a Ph.D. in Microbiology at the University of Milan. He joined the Institute for Research in Biomedicine in Bellinzona in 2002 as Head of the Mucosal Immunology lab. His research is focused on understanding mechanisms regulating the mucosal adaptive immune response as well as mutualism with intestinal commensals. He is also full professor of Biology at the Medical School of the University of Milan.
Holds a Ph.D. in Natural Sciences from the Swiss Federal Institute of Technology in Zürich (ETHZ). With over 30 years of experience in the pharmaceutical industry, he joined MV Biotherapeutics as CEO and Board Member in august 2020. Previous most relevant experiences were with Helsinn Advanced Synthesis from 1999 until 2008 as Head Business Development of the CDMO activities of the Helsinn group and Cerbios-Pharma CEO from 2009 until 2020. Haering was also active as Board Member of Lipidor (NASDAQ, LIPI.ST) from 2014 until 2020 helping the company changing strategy ready for the successful IPO of September 2019.